Basic Information
MIACALCIC INJECTION 100 iu/ml
INJECTION
Regulatory Information
SIN04735P
June 26, 1990
Prescription Only
Therapeutic
INTRAVENOUS, SUBCUTANEOUS, INTRAMUSCULAR
August 10, 2023
June 4, 2025
XH05BA01
Company Information
ZUELLIG PHARMA PTE. LTD.
ZUELLIG PHARMA PTE. LTD.
Active Ingredients
Strength: 100 iu/ml
Detailed Information
Contraindications
**CONTRAINDICATIONS** Known hypersensitivity to synthetic salmon calcitonin or to any of the excipients (see sections WARNINGS AND PRECAUTIONS, ADVERSE DRUG REACTIONS and DESCRIPTION AND COMPOSITION – EXCIPIENTS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**INDICATIONS** Miacalcic solution for injection or infusion is indicated for the treatment of: **Bone pain associated with osteolysis and/or osteopenia** **Paget’s disease of bone (osteitis deformans) only in patients who do not respond to alternative treatments or for whom such treatments are not suitable** **Hypercalcemia and hypercalcemic crisis due to** - tumoral osteolysis secondary to breast, lung or kidney carcinoma, myeloma and other malignancies, - hyperparathyroidism, immobilization or vitamin D intoxication, for both the acute treatment of emergencies and the prolonged treatment of chronic hypercalcemia, until specific therapy of the underlying condition proves effective. **Neurodystrophic disorders (synonymous with algodystrophy or Sudeck’s disease)** Caused by various etiological and predisposing factors such as post-traumatic painful osteoporosis, reflex dystrophy, shoulder-arm syndrome, causalgia, drug-induced neutrophic disorders. **Adjuvant therapy of acute pancreatitis**